Search our website

There are 10 results.

After Ablynx, is an acquisition of Galapagos next?

Monday 19 February 2018
The Gent biotech company Ablynx has been acquired by pharmaceutical giant Sanofi for 3.9 billion euros. The French Sanofi beat the Danish company Novo Nordisk to the deal after a much higher offer…

Sanofi acquires Ablynx for €3.9 billion

Monday 29 January 2018
Sanofi and Ablynx entered into a definitive agreement under which Sanofi will offer to acquire all of the outstanding ordinary shares, including shares represented by American Depositary Shares (A…

Ablynx' caplacizumab receives fast track designation from FDA

Wednesday 26 July 2017

The fast track designation would allow caplacuzimab to enter the market 6 to 10 months earlier

Strategic Ablynx - Sanofi collaboration for up to 8 Nanobodies in immunology and inflammation

Thursday 20 July 2017

Ablynx announced that it has entered into a research collaboration and global exclusive licensing agreement with Sanofi initially focused on developing and commercialising Nanobody®-based therapeutics for the treatment of various immune-mediated inflammatory diseases.

ABLYNX APPOINTS MARKUS EWERT AS CHIEF BUSINESS OFFICER

Tuesday 13 June 2017
Ablynx today announced the appointment of Markus L.E. Ewert, PhD, MBA, as Chief Business Officer (CBO). Effective from 20 June 2017, Dr Ewert will lead the Company's business development and corpo…

ABLYNX SUBMITS A MARKETING AUTHORISATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR CAPLACIZUMAB

Monday 6 February 2017
In the Phase II TITAN study, treatment with caplacizumab significantly reduced the time to platelet count normalisation and the number of recurrences of aTTP while on drug treatment. Post-hoc anal…

MERCK REPORTS ENCOURAGING RESULTS WITH ABLYNX' PSORIASIS NANOBODY

Friday 27 January 2017
• Primary objective of safety and tolerability met • In the three highest dose groups, 100% of patients achieved a 75% or greater reduction in disease activity compared to 0% for placebo • The…

ABLYNX INITIATES PHASE IIb STUDY OF INHALED ANTI-RSV NANOBODY

Thursday 12 January 2017
ALX-0171 is a first-in-class inhaled Nanobody® developed for the treatment of RSV infections. The drug was found to be safe and well tolerated in a Phase IIa study in hospitalized infants with a R…

Ablynx to present at the 35th annual J.P. Morgan Healthcare Conference

Thursday 5 January 2017

Ablynx will present at the 35th Annual J.P. Morgan Healthcare Conference on Thursday 12 January, at 1.30 am CET (Wednesday 11 January 2017 at 4:30 p.m. PST).

Ablynx quickly delivers on Novo Nordisk collaboration

Wednesday 30 November 2016
Almost exactly one year after Ablynx announced its collaboration with Novo Nordisk, their research project for the Danish pharma giant has reached a discovery milestone. Ablynx is developing a mul…

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

V-Bio Ventures XpandInnovation UGent Flanders.bio Turnstone Janssen Biowin KU Leuven GSK Itera Life Science

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.